SKOKIE, Ill.--(BUSINESS WIRE)--
Exicure, Inc. (XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced a poster presentation at ARVO 2019 Annual Meeting in Vancouver, British Columbia. The poster is titled “Spherical Nucleic Acids Exhibit Enhanced Distribution and Persistence Compared to Linear Oligonucleotides in Rat Eyes Following Intravitreal Administration” and will be presented by Bart Anderson, Director of R&D at Exicure.
Session Date/Times: Tuesday, April 30, 2019 from 11:45 am to 1:30 pm PDT and 4:30 pm to 5:30 pm PDT
Presentation number: 3378, Poster board number A0148
Session track: Drug delivery, drug and gene delivery system, implant delivery
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. We believe Exicure's proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure's lead program is in a Phase1b/2 trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL. www.exicuretx.com